Biotage

Share Issue/Capital Change • Sep 5, 2024

Issue and re-purchase of class C shares for incentive program

The Board of Directors of Biotage AB (publ) ("Biotage") has today resolved, by virtue of the authorisation by the Annual General Meeting held on April 25, 2024, to issue and immediately thereafter re-purchase 286,440 class C shares. The shares are issued and re-purchased in accordance with the incentive program LTIP 2024 which was adopted by the Annual General Meeting held on April 25, 2024.

Danske Bank A/S, Danmark, Sverige Filial, will subscribe for the entire issue of new class C shares at a subscription price of SEK 1.39 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors' resolution, be re-purchased by Biotage for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2024.

The purpose of the re-purchase is to ensure delivery of shares to participants and to secure social contributions arising as a result of LTIP 2024. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

Contacts

Torben Jörgensen, Interim President & CEO Tel: +46-707 49 05 84, torben.jorgensen@biotage.com

About Biotage

Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes.

Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT). Website: www.biotage.com

Attachments

Issue and re-purchase of class C shares for incentive program